Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Too much risk here for Amryt and me..
NEEDHAM, Mass. (AP) _ Chiasma Inc. (CHMA) on Wednesday reported a loss of $30.5 million in its first quarter.
The Needham, Massachusetts-based company said it had a loss of 49 cents per share.
The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 30 cents per share.
The biopharmaceutical company posted revenue of $1.9 million in the period.
No doubt the house brokers will crank out the usual synergy blah blah tomorrow but it looks like the market has decided who the winners and losers are in this deal.
Down to $11.9 pre market
Yep I sold..
Something doesn't add up..
Still have my CVR's
It's a surprising split of ownership. Chiasma had a market cap of just $164m / £118m at close last night vs Amryt which was capitalised at £358m. So for Chiasma to be getting 40% of the combined entity is quite a coup for them... Where the LSE share price will end up is hard to say, as it depends how the market values the synergies created + the combined pipeline.
Amryt itself was cash neutral for the quarter, so at least it has stability in it's existing operations. The balance sheet remains messy though, a significant equity raise to clear debt & back the pipeline would make a lot of sense in the next 6 months IMO. Good for them though, they need scale to be successful and they are certainly giving it a go.
Chiasma $3.9 pre-market implying AMYT london line at 150p. Feels like AMYT london share will drop a bit when the US opens.
MYCAPSSA looks like it could have potential..
And they have a few more in Phase 3 trials.
Still not sure
Well they are up 50% to 4.25 pre market..
Amryt looking lower marginally
Looks like a great deal...
For Chiasma. Just on market cap it looks more like 70/30 then 60/40
Chiasma has $115 million in cash but measly revenues and its burning thru cash like a bat out of he'll.
Certainly some unusual share volumes both here and in the US over the last few days given that the usual daily volumes tend to be quite small. I also wonder about the NASDAQ listing effectiveness. Initially when they listed in the US it looked like they saw NASDAQ being the primary listing but recent insider purchases seem to have been on AIM?
Not today anyway ,son there rea zero trades.
Enigma..over 1 million traded yesterday and nada today..
Well they ain't buying aggressively..
Thanks for that Bronxville - good to see that Amryt seem to be gaining traction with US funds
. Amryt Pharma plc (NASDAQ: AMYT)
Number of Hedge Fund Holders: 8
Amryt Pharma plc (NASDAQ: AMYT) is a United Kingdom-based firm that concentrates on the development and delivery of new drugs to help the patients with rare and orphan diseases. The company has a growing commercial business and invests heavily in research and development. The company makes Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It has operations in the Americas, Europe, and the Middle East. The firm was founded in 2015.
It has a market cap of more than $506 million and posted a revenue of more than $182 million in December 2020, an increase of more than $130 million compared to the previous year. The 52-week share price range of the company stock is $15-$10. Earlier today, it was trading at $13.8. Last year, the company confirmed that its research into a genetic skin disorder had got encouraging results. A request for production of the new treatment will be filed this year. The firm is placed eighth on our list of 10 cheap pharmaceutical stocks for 2021.
The company is also getting the attention of the smart money, as 8 hedge funds tracked by Insider Monkey reported owning stakes in the company at the end of the fourth quarter, up from 4 funds a quarter earlier.
https://finance.yahoo.com/news/10-cheap-pharmaceutical-stocks-2021-132008483.html
Selling large blocks..
Not too worried at current levels but Amryt has been stagnant money for ages..
Maybe they need to refinance their debt.
Bought 110,000 shares yesterday, usual pattern, lift is coming.
Amryt Pharma’s Juxtapid (lomitapide) had a 7-point jump in its Likelihood of Approval (LoA) in familial chylomicronaemia syndrome (FCS) on the heels of positive data from an investigator-led Phase III trial.
https://www.clinicaltrialsarena.com/comment/loa-update-amryts-juxtapid-sees-7-point-surge-in-us-approval-prospects-in-familial-chylomicronaemia/
Amryt Pharma’s Juxtapid (lomitapide) had a 7-point jump in its Likelihood of Approval (LoA) in familial chylomicronaemia syndrome (FCS) on the heels of positive data from an investigator-led Phase III trial.
https://www.clinicaltrialsarena.com/comment/loa-update-amryts-juxtapid-sees-7-point-surge-in-us-approval-prospects-in-familial-chylomicronaemia/
Might be a little bit of nibbling across the pond...
A close above $15 could potentially send a strong buy signal
Quite realistic, IMO: with the continual flow of positive RNSes, coupled with similar ones to follow, particularly with the big one for the licence, that target could well be surpassed.
That was yesterday and yet no one gives a fiddlers...Can't understand how management can't generate any interest in Amryt.
Paps..OO is an animal..still holding..3 or 4 spinoffs coming..
Not sure yet about SPC..Think its for another venture but its on my radar..
Its just a shell with a massive share count at the moment.